Due to the Corona Pandemic and the resulting restrictions on holding investor events, InnoMedica is planning to organise events online as part of this capital increase - you will be informed of the dates as soon as possible.Sign up for online events.Order investor documents.
Please send me the InnoMedica Newsletter.
Together for the patient – planning of clinical trials in collaboration with Swiss Group for Clinical Cancer Research (SAKK)
Improved efficacy despite dose reduction due to multi-level glycan targeting – basic therapeutic cytostatic agents for the first time applied specifically in tumor tissu
Reduced side effects – healthy tissue is optimally protected by the liposomal encapsulation of the drug
Existing agent subject to innovation – simpler registration with Swissmedic due to already approved active agent
Patented technology – based on many years of research
Chemotherapy is considerably more tolerable by the use of targeting systems reducing side-effects to a minimum
Drug delivery is poised to change the way doctors practice medicine – The Scientist, 2014
Operating license from Swissmedic for proprietary clean room facility for GMP-production obtained
©Copyright Innomedica 2016